NCT02381379: Malaysia stop tyrosine kinase inhibitor trial (MSIT): IFN-α vs. observation in CML patients off TKI after deep molecular remission × 2 years. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.